Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Chemoradiation and Surgery for High-Risk Soft Tissue Sarcoma
NCT02050919Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Dec 2013
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in soft tissue sarcoma (STS), sponsored by OHSU Knight Cancer Institute. Started Dec 2013; status: completed.
02
Drugs
sorafenib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02050919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02050919.